.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,853,984

« Back to Dashboard

Details for Patent: 5,853,984

Title: Use of nucleic acid ligands in flow cytometry
Abstract:This invention discloses the use of high-affinity oligonucleotide ligands in flow cytometry diagnostic applications. Specifically, DNA ligands having one or more fluorophore molecules attached are disclosed which are useful in flow cytometry.
Inventor(s): Davis; Ken (Los Altos, CA), Jayasena; Sumedha (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 07, 1995
Application Number:08/479,729
Claims:1. A method for detecting the presence of a target compound in a substance which may contain said target compound, wherein said target compound or said substance is particulate, comprising:

a) identifying a nucleic acid ligand from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of said target compound, by the method comprising:

i) contacting the candidate mixture with said target compound, wherein nucleic acids having an increased affinity to said target compound relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

iii) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids; and

iv) identifying said nucleic acid ligand;

b) attaching said nucleic acid ligand with a fluorophore to form a fluorophore-labelled nucleic acid ligand;

c) mixing said fluorophore-labelled nucleic acid ligand with a substance which may contain said target compound under conditions suitable for binding of the fluorophore-labelled nucleic acid ligand to said target compound; and

d) analyzing said mixture by flow cytometry to detect whether said fluorophore-labelled nucleic acid ligand bound to said target compound in said substance, whereby the presence of a target compound in a substance can be detected.

2. The method of claim 1 wherein said fluorophore of said fluorophore labelled nucleic acid ligand is selected from the group consisting of fluorescein, rhodamine, Cy5 reactive dye, Cy3 reactive dye, allophycocyanin, peridinine chlorophyll-a protein (PerCP), phycoerythrin, and green fluorescein protein (GFP).

3. The method of claim 1 wherein said substance is a biological fluid.

4. The method of claim 1 wherein said substance comprises cells.

5. The method of claim 3 wherein said substance is selected from the group consisting of blood, plasma, serum, sputum, urine, semen, cerebrospinal fluid, bronchial aspirate, and macerated tissue.

6. The method of claim 5 wherein said substance is selected from the group consisting of blood, plasma, serum and macerated tissue.

7. The method of claim 1 wherein said target compound is on the surface of a cell.

8. The method of claim 1 wherein said target compound is intracellular.

9. The method of claim 8 wherein said target compound is cytoplasmic.

10. The method of claim 1 wherein unbound fluorophore-labelled nucleic acid ligand is removed from said mixture between steps c) and d).

11. A method for detecting the presence of a soluble target compound in a substance which may contain said target compound by flow cytometry comprising:

a) immobilizing on a particulate solid support a capture molecule capable of binding to said target compound;

b) exposing a substance which may contain said target compound to said capture molecule;

c) adding to said capture molecule:target compound complex a fluorophore-labelled detector molecule capable of binding to said target compound; and

d) detecting said capture molecule:target compound:detector molecule complex by flow cytometry, wherein said capture molecule, detector molecule or both are a nucleic acid ligand to said target compound, wherein said nucleic acid ligand is identified by the method comprising:

i) preparing a candidate mixture of nucleic acids:

ii) contacting the candidate mixture with said target compound, wherein nucleic acids having an increased affinity to said target compound relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

iii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture,

iv) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, and

v) identifying said nucleic acid ligand.

12. The method of claim 11 wherein said particulate solid support is a bead.

13. The method of claim 11 wherein steps b) and c) are done simultaneously.

14. A method for detecting the presence of a non-nucleic acid target compound in a substance which may contain said non-nucleic acid target compound, wherein said non-nucleic acid target compound or said substance is particulate, comprising mixing said substance with a fluorophore labelled nucleic acid ligand which is capable of binding to said non-nucleic acid target compound and analyzing said mixture by flow cytometry to detect whether said fluorophore labelled nucleic acid ligand bound to said non-nucleic acid target compound in said substance, whereby the presence of a non-nucleic acid target compound in a substance can be detected, wherein said nucleic acid ligand is identified by the method comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting said candidate mixture of nucleic acids with said target compound, wherein nucleic acids having an increased affinity to said target compound relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

d) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids; and

e) identifying said nucleic acid ligand.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc